<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Ensemble Nails Deal with Bristol-Myers Squibb to Discover New Drugs</title>
	<atom:link href="http://www.xconomy.com/boston/2009/04/15/ensemble-nails-partnership-with-bristol-myers-to-discover-new-drugs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2009/04/15/ensemble-nails-partnership-with-bristol-myers-to-discover-new-drugs/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 21 Nov 2009 22:30:41 -0600</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Latest Financings and Deals: Santen, Synageva, Ensemble, Lycera &#124; IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky</title>
		<link>http://www.xconomy.com/boston/2009/04/15/ensemble-nails-partnership-with-bristol-myers-to-discover-new-drugs/comment-page-1/#comment-53798</link>
		<dc:creator>Latest Financings and Deals: Santen, Synageva, Ensemble, Lycera &#124; IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky</dc:creator>
		<pubDate>Thu, 16 Apr 2009 14:01:23 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=20293#comment-53798</guid>
		<description>[...] Ensemble Discovery has struck a $40M+ deal with Bristol-Myers Squibb with $5M being paid upfront. Ensemble&#8217;s technology focuses on Ensemblins, a new class of drug drugs that are hybrids between small molecules and biologics. The goal is to create a small molecule-like drug that can hit biologic targets that are not accessible by current small molecules. Some of the targets are reachable by biotech drugs, biologics, etc., but are hard to treat using protein-based drugs because they are lifelong chronic diseases. [Xconomy] [...]</description>
		<content:encoded><![CDATA[<p>[...] Ensemble Discovery has struck a $40M+ deal with Bristol-Myers Squibb with $5M being paid upfront. Ensemble&#8217;s technology focuses on Ensemblins, a new class of drug drugs that are hybrids between small molecules and biologics. The goal is to create a small molecule-like drug that can hit biologic targets that are not accessible by current small molecules. Some of the targets are reachable by biotech drugs, biologics, etc., but are hard to treat using protein-based drugs because they are lifelong chronic diseases. [Xconomy] [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: MedCity morning read, Wednesday, April 15 : MedCity News</title>
		<link>http://www.xconomy.com/boston/2009/04/15/ensemble-nails-partnership-with-bristol-myers-to-discover-new-drugs/comment-page-1/#comment-53671</link>
		<dc:creator>MedCity morning read, Wednesday, April 15 : MedCity News</dc:creator>
		<pubDate>Wed, 15 Apr 2009 13:07:12 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=20293#comment-53671</guid>
		<description>[...] Ensemble nails deal with Bristol-Myers Squibb to discover new drugs (Xconomy Boston) [...]</description>
		<content:encoded><![CDATA[<p>[...] Ensemble nails deal with Bristol-Myers Squibb to discover new drugs (Xconomy Boston) [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
